The Journal of Immunology

IgM, FcµRs, and Malarial Immune Evasion

Daniel M. Czajkowsky, Ali Salanti, Sisse B. Ditlev, Zhifeng Shao, Ashfaq Ghumra, J. Alexandra Rowe and Richard J. Pleass

Supplementary Data	http://www.jimmunol.org/cgi/content/full/184/9/4597/DC1
References	This article **cites 64 articles**, 25 of which can be accessed free at: http://www.jimmunol.org/cgi/content/full/184/9/4597#BIBL
Subscriptions	Information about subscribing to *The Journal of Immunology* is online at http://www.jimmunol.org/subscriptions/
Permissions	Submit copyright permission requests at http://www.aai.org/ji/copyright.html
Email Alerts	Receive free email alerts when new articles cite this article. Sign up at http://www.jimmunol.org/subscriptions/etoc.shtml

IgM, FcμRs, and Malarial Immune Evasion

Daniel M. Czajkowsky,*,† Ali Salanti,‡ Sisse B. Ditlev,‡ Zhifeng Shao,*,§
Ashfaq Ghumra,¶,‖ J. Alexandra Rowe,¶ and Richard J. Pleass‖

IgM is an ancestral Ab class found in all jawed verte-brates, from sharks to mammals. This ancient ancestry is shared by malaria parasites (genus *Plasmodium*) that infect all classes of terrestrial vertebrates with whom they coevolved. IgM, the least studied and most enig-matic of the vertebrate Igs, was recently shown to form an intimate relationship with the malaria parasite *Plasmodium falciparum*. In this article, we discuss how this association might have come about, building on the recently determined structure of the human IgM pen-tamer, and how this interaction could affect parasite survival, particularly in light of the just-discovered FcμR localized to B and T cell surfaces. Because this parasite may exploit an interaction with IgM to limit immune detection, as well as to manipulate the im-mune response when detected, a better understanding of this association may prove critical for the development of improved vaccines or vaccination strategies. *The Journal of Immunology*, 2010, 184: 4597–4603.

Ancient ancestry and crucial functions of IgM

Immunoglobulin M is the oldest and only isotype of Ab that is expressed by all species of vertebrates. Unlike most other isotypes, there are two classes of IgM: an Ag-specific (or immune) IgM class that is produced in response to ex-posure to specific pathogens and a low-affinity, more broadly reactive (so-called "natural" or "nonimmune") IgM class that is synthesized without prior exposure to any particular Ag. This latter form, apparently designed to recognize common motifs of widespread foreign invaders as part of the first line of host defense, is likely responsible for the conservation of this isotype among distantly related vertebrates (1). Moreover, probably befitting their common ancestry, IgM molecules from all species studied to date are higher-order multimeric complexes (predominantly pentamers in human plasma), a physical property that endows the molecule with extraor-dinary functions, including multivalent binding to Ags and receptors (2–4).

Natural IgM produced by peritoneal B-1 cells is an im-portant mediator of innate immunity, controlling the dis-semination of viruses and bacteria (3, 4). A subset of these B-1 cells can also contribute to the production of immune IgM and provide long-term T cell-independent immunity against reinfection (5), although immune IgM can also be produced in a T cell-dependent manner by conventional B-2 cells in the spleen and lymph nodes (6). IgM constitutes ~10% of human plasma Ig, and levels of IgM are ~25% greater in females than in males (7, 8), a finding that led to the notion that males are significantly more susceptible to infections than are females (9, 10). Because selective IgM deficiency is rare in humans, an understanding of the importance for IgM in immunity has come from studies using secretory IgM-deficient (IgM$^{-/-}$) mice (3, 4, 11). These studies clearly show that serum IgM primes the ensuing IgG response and that IgM is particularly effective at neutralizing and agglutinating blood pathogens, particularly those that reside within cells, by inhibiting pathogen transfer from cell to cell (11). Such findings show that IgM can have a profound impact on protective immunity and, in terms of possible mechanisms, point to the in-volvement of interactions between the Fc domain in IgM and effector molecules, such as complement and FcRs, in medi-ating at least some of this immunity.

A role of IgM in human malaria

As with IgM, malarial parasites of the genus *Plasmodium* have been found in all classes of terrestrial vertebrates, including reptiles and birds. Thus, they likely are a long-standing ver-tebrate pathogen against which a vigorous immune response involving IgM would be commonly expected. Indeed, parasite-specific IgM was shown to limit parasite replication and prime memory cell generation, and it is a more potent adjuvant than *Bordetella pertussis* in experiments with murine malarias (12, 13). Natural IgM is also an endogenous adju-vant for vaccine-induced protective CD8$^+$ T cell responses

*Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, VA 22908; †Shanghai Institute of Applied Physics, Chinese Academy of Sciences; §Ministry of Education Key Lab for Systems Biomedicine and National Lab for Oncogenes, Shanghai JiaoTong University, Shanghai, China; ‡Centre for Medical Parasitology, Department of International Health, Immu-nology, and Microbiology, University of Copenhagen, Copenhagen University Hospital, Rigshospitalet, Denmark; ¶Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh; and ‖Parasite Biology and Immunogenetics Research Group, Institute of Genetics, Queen's Medical Centre, Uni-versity of Nottingham, Nottingham, United Kingdom

against intracellular parasites (14). Given these considerations, it is somewhat surprising that so little work has been published on the role of IgM in human malaria. Natural IgM is known to bind to the surface of *Plasmodium falciparum*-infected erythrocytes via the Fc, and this was shown to correlate with severe malaria in laboratory strains and field isolates (15, 16). Only some *P. falciparum* strains bind natural IgM, and this property is seen in parasites with specific virulence-associated adhesion phenotypes, including rosetting (15), and chondroitin sulfate A (CSA)-binding linked to placental malaria infection (17, 18). *P. falciparum* strains showing other common adhesion phenotypes, including CD36 and ICAM-1 binding, do not seem to bind natural IgM (15). Therefore, although nonimmune IgM binding is only shown by a subset of *P. falciparum* isolates, it is linked to the most serious clinical effects of malaria. A greater understanding of the role of nonimmune IgM in these host–parasite interactions has the potential to contribute new insights and interventions against life-threatening disease.

Importance of pathogen Fc-binding proteins

To evade Fc-mediated destruction, pathogens have evolved to produce Fc-binding proteins; those expressed by bacteria and viruses for IgG or IgA have been intensively studied (19–21). These proteins help pathogens to avoid host immune responses by preventing pathogen-specific Abs from interacting with host FcRs and, therefore, interfere with effector functions of Ab, such as phagocytosis and complement activation (19–21). The existence of IgM Fcμ-binding proteins from pathogens is less well documented than for IgG and IgA. This might be because of difficulties in differentiating low-affinity F(ab)′₂-mediated pathogen binding by natural IgM Abs from bona fide Fc–receptor interactions. Nonetheless, IgM-binding proteins have been described for several protozoa, including *Toxoplasma gondii* (22) and pathogenic species of *Trypanosomatidae* (23). Recently, we provided the first detailed molecular characterization of an IgM Fc-binding protein from the malaria parasite *P. falciparum* (16).

An Fcμ-binding protein expressed by Plasmodium falciparum: P. falciparum erythrocyte membrane protein 1

IgM binding by *P. falciparum*-infected erythrocytes occurs via the parasite variant Ag, *P. falciparum* erythrocyte membrane protein one (PfEMP1), found on the surface of infected erythrocytes (15, 16). PfEMP1 variants are encoded by *var* genes, and each parasite contains 50–60 *var* genes in its genome (24, 25), with only one variant expressed on the infected erythrocyte surface at a time (26). The *var* gene repertoires of different *P. falciparum* isolates have very little overlap, resulting in extensive diversity among different parasite isolates (27). PfEMP1 molecules are composed of Duffy binding-like (DBL) domains classified into six types (α, β, γ, δ, ε, and X) and cysteine-rich interdomain region domains classified into three types (α, β, and γ) (28). Individual *var* genes differ from each other by the number and type of these domains. A number of different domains from specific PfEMP1 variants expressed by IgM-binding–infected erythrocytes of different parasite strains were shown to bind nonimmune IgM (Table I), including our identification of IgM binding by DBL4β from the PfEMP1 variant *var1* in the TM284 isolate (16). It has not been possible to define a spe-

Table I. *Known IgM-binding DBL domains from* P. falciparum

| PfEMP1 Variant	Domain	Reference
FCR3S1.2*var*1	CIDR	29
TM284S2*var*1	DBL2β	30
FCR3*var*1*csa*	DBL7ε	31
FCR3*var*2*csa*	DBL6ε	31
3D7*var*2*csa*	DBL2-X, DBL5ε, DBL6ε	32
TM284*var*1	DBL4β	16

cific sequence motif within these various domains that is responsible for the ability to bind nonimmune IgM.

Identifying the binding site for PfEMP1 on the IgM molecule

Using recombinant domain-swapped Abs, IgM mutants, and blocking mAbs, we defined the region of the IgM molecule bound by PfEMP1 (16). In particular, these experiments showed that PfEMP1 binds to the Cμ4 domain of polymeric IgM (16), at a region conserved with those on IgG and IgA recognized by Fc-binding proteins from bacteria and viruses (Fig. 1) (19–21). The binding site on IgM was also shared by five distinct parasite strains (two rosetting and three CSA binding), suggesting that diverse parasite isolates expressing distinct PfEMP1 variants all bind to the same (or similar) site on the human IgM molecule. Recent work from our laboratories has shown that the laboratory isolate 3D7, which was panned on CSA to express the PfEMP1 variant *var2csa* (33), also interacts with IgM via the Cμ4 domain. In this case, the DBL5ε domain in *var2csa* binds IgM (A. Salanti, S.B. Ditlev, and R.J. Pleass, unpublished data). The binding of IgM to recombinant 3D7 DBL5ε was not inhibited by soluble CSA, implying that the CSA-binding sites on the DBL domains do not overlap with those used by IgM. Recombinant *var2csa* single domains were shown to bind promiscuously to a number of glycosylated receptors that the native *var2csa* does not bind (33). However, using full-length recombinant FCR3 *var2csa*, we verified that IgM interacts with the complete protein, providing validation for the results with the individual domains (A. Salanti, S.B. Ditlev, and R.J. Pleass, unpublished data).

Structural insights into PfEMP1–IgM interactions

The use of a similar IgM-binding site by distinct PfEMP1 variants suggests the possibility of a similar structural mechanism

**FIGURE 1.** Contact areas of Fc with pathogen Fc-binding proteins. Ribbon diagrams of the IgM–Fc in complex with the DBL4β domain of the TM284var1 variant of PfEMP1 (*left panel*) and the IgG–Fc in complex with domain C2 of staphylococcal protein G (*right panel*). The structure of the IgM–DBLβ complex is described in Fig. 2. Both proteins bind at analogous positions in the interdomain region of the Ig Fc.

of binding to IgM. To determine whether there is a common IgM interaction site on these diverse *P. falciparum* DBL domains, we modeled the previously described IgM-binding DBL domains (Table I) onto known DBL structures and tried to dock these molecules into a recent model of human IgM (34). This model of IgM, based on the known bent structure of IgE and supported by direct cryo-atomic force microscopy images, shows IgM to be a mushroom-shaped molecule, with a central region formed by the Cμ3/Cμ4 domains protruding out of the plane formed by the Cμ2/Fab domains. The residues Pro^{394}–Pro^{397} and Pro^{444}–Val^{447} in the Cμ4 domain, previously implicated in PfEMP1 binding, are localized near the junction between two monomers (16) and, therefore, can form the binding pocket for PfEMP1, while explaining the requirement for a polymeric structure.

Although it might be expected that there are many ways by which such large proteins could possibly interact, a number of observations place strict constraints on potentially viable models, including the narrowness of the binding pocket (with a width of a little more than only two helices), the central disposition of the IgM-binding domains within the full PfEMP1 sequence (which constrains the possible locations of the termini of the IgM-binding domain), the markedly limited solvent accessibility of these domains within the native PfEMP1 (33, 35, 36), and the localization of ligand-binding residues in other DBL domains to the loops in subdomain 2 (35, 36).

Under these strict constraints, we were able to identify only a single plausible DBL–IgM model (Fig. 2A). In this structure, the DBL domain, orientated roughly perpendicular to the Cμ2/Fab plane, binds to the side of the central IgM stem, in between two IgM monomers that project radially (Fig. 2A, Supplemental Video 1). The predominant contacts to the IgM molecule are mediated by loops within subdomain 2, which directly contact the opposing residues of neighboring IgM monomers (Table II), including those between the Pro^{444}–Val^{447} loop in IgM (16). Additional contacts away from this region involve a small helix near the DBL C terminus (residues Gln^{429}–Glu^{437}) and the other Pro^{394}–Pro^{397} loop of IgM (16). Although this model satisfies all of the aforementioned constraints, what was particularly striking about this disposition of the DBL domain was the presence and number of its charged residues that are immediately adjacent to oppositely charged residues on the IgM surface (Fig. 2B). Although these residues are not strictly conserved between different IgM-binding domains, a similar set of charged residues is found in all of the characterized IgM-binding DBL domains (Table II). Moreover, inspection of these regions in the known structures of members of the DBL family, which are from proteins that do not bind IgM (e.g., EBA-175, and PKα-DBL) or have been shown not to bind IgM (e.g., DBL3X), reveals an absence of charged residues similar to this set (data not shown).

Such a binding mechanism involving similarly charged, but not strictly conserved, residues from DBL domains of different subclasses, which, moreover, are not shared by all members of any single subclass, suggests that there was not an ancestral IgM-binding DBL domain from which these domains are derived. Instead, IgM binding may be an emergent property of certain DBL domains that resulted from some other common trait of these domains. Interestingly, the most characterized IgM-binding domains (Table II) are located proximal to the

FIGURE 2. Homology-based model of the IgM–DBL4β complex. *A,* The mushroom-shaped structure of IgM (white) is based on the known bent structure of IgE and direct cryo-atomic force microscopy images (described in Ref. 34) and was left unaltered in the modeling with DBL4β. The novel homology model of TM284var1 DBL4β (blue) shown is based on the known structures of members of the DBL family (31, 35–39). The DBL4β domain was manually docked onto the IgM structure, taking heed of constraints described in the text. The *top* and *middle panels* show views of the IgM–DBL4β complex looking down onto the protruding side of the IgM molecule and from the side, respectively. The residues in IgM identified in mutational analyses to be critical for binding to TMR284var1 DBL4β (Pro^{394}–Pro^{397} and Pro^{444}–Pro^{447} of the Cμ4 domain) are shown in orange (16). *B,* Regions within subdomain 2 of TM284 DBL4β (blue) and FCR3 DBL6ε (green) domains that directly interact with IgM (white). A pocket of charged residues found at the monomer–monomer interface of IgM (inset) is directly adjacent to oppositely charged residues found in the DBL domain loops, suggesting a mechanism of association between members of the DBL protein family and human IgM molecules. Notice that the modeled TM284 DBL4β domain in this region has a much longer loop than in the FCR3 DBL6ε domain; however, this loop is easily accommodated within the DBL–IgM interface, and with this interaction, increases the apparent charge complementarity at this DBL–IgM interface.

erythrocyte plasma membrane. As a result, the possible orientations of the IgM molecule, when bound to PfEMP1, would presumably be severely limited, owing to the presence of the nearby erythrocyte membrane (compared with a more membrane-distal binding). Hence, it may be important for the function of these IgM Fc-binding proteins to not just interact

Table II. *Amino acid residues in DBL domains predicted from molecular modeling to interact with IgM*

TM284var1 DBL4β	FCR3var2csa DBL6ε	3D7var2csa DBL5ε	FCR3var1csa DBL7ε
Lys1782	Arg2494	None	None
Glu1779	Glu2491	Asp2149	Glu3082
Arg1764	Arg2481	Lys2141	Lys3072
Glu1663	None	Glu2079	Glu3005
Glu1665	None	Asp2080	Glu3007

with IgM, but also to have the IgM molecule, in essence, distinctly oriented with respect to the red cell membrane. This may be necessary to prevent or perturb the access of IgM to host effector proteins, such as complement C1q, or, perhaps more intriguingly, to actually promote the binding of IgM to host receptors (Fig. 3).

Why do pathogens bind the Fc of IgM?

It is unknown why *P. falciparum* has evolved an IgM Fcμ-binding protein. In fact, this interaction may be part of a more general set of interactions that have evolved between *P. falciparum* and IgM, including a recently suggested inhibitory role of IgM as a novel component of the tetraspanin network on B cells (40), and in hepatocyte invasion by sporozoites (41). However, in this brief review, we focus on the possible functional consequences of the PfEMP1–IgM interaction. As summarized in Fig. 3, these include interference with immunological signaling and clearance mechanisms, blocking the binding of specific Abs, or as a way of enhancing infected erythrocyte sequestration in the microvasculature or placenta.

FIGURE 3. Possible functional consequences of the PfEMP1–IgM interaction. Shown are several potential IgM–effector associations that could be altered as a result of the known DBL–IgM interaction. As described more fully in the text, these include those with the recently identified FcμR protein found in T cells, where it could play a role in mediating immunological synapse formation (*A*), and in B cells, where it might be involved in activating these cells through interactions with BCR [and CR1/2 (*B*)]; the Fcα/μR protein predominantly localized to FDCs (*D*); the endothelial receptor CD300LG (*F*); and the potent activator of the classical complement pathway C1q (*G*). Also depicted are the possibilities for direct interactions between PfEMP1 proteins and BCR complexes in B cells, which could promote activation of these complexes through clustering (*C*), and a blocking of potential Ags on infected RBCs as a result of a shielding mechanism of IgM bound to PfEMP1 (*E*).

Interference with FcμR

The recent identification of a bona fide high-affinity FcμR for IgM expressed by CD19⁺ B cells (including memory B cells), CD4⁺/CD8⁺ T cells, and CD56⁺/CD3⁻ NK cells may provide the target for interference by malaria parasite DBL domains (42). Although the function of FcμR in these cells is not understood, ectopic expression of this receptor was found to affect cell survival and proliferation, and a role in B cell activation has been suggested (42). Infection with *P. falciparum* malaria is known to induce polyclonal B cell activation, leading to a marked hypergammaglobulinemia and elevated titers of autoantibodies (43). Therefore, binding by parasite PfEMP1 proteins to IgM may interfere with the interaction of IgM with FcμR on B cells in a way that favors the induction of proliferative responses by the parasite. The benefit for the parasite of such a rampant B cell activation is not understood.

Intriguingly, increased Ag retention by marginal zone B cells and germinal center formation also depend on CR1 (CD35) and CR2 (CD21), the latter being responsible for EBV entry into B cells (44). EBV-infected B cells occasionally undergo malignant transformation in vivo, giving rise to Burkitt's lymphoma, a tumor that commonly occurs in areas of Africa hyperendemic for malaria (45, 46). Therefore, the ability of PfEMP1 to interfere with signals induced by FcμR might promote cellular proliferation and predispose the B cell to become malignant upon infection by EBV. Because children affected by Burkitt's lymphoma often present with chronic malaria, it would be interesting to determine whether parasite isolates derived from these children also bind IgM.

FcμR is also constitutively expressed on CD4⁺ and CD8⁺ T cells, although its function on these cells awaits elucidation (42). The receptor may allow the T cell to interact optimally with the IgM BCR or IgM immune complexes on B cells, facilitating immunological synapse formation between the two cell types and thereby enhancing B cell activation and memory induction. It may also trigger IgM-dependent cell-mediated cytotoxicity by CD8⁺ T cells, already known to play an important role in immunity against liver-stage parasites (47). The ability of PfEMP1 to bind IgM could significantly interfere with these FcμR functions and provide a significant advantage to a parasite under attack from parasite-specific or natural IgM. These possibilities need to be investigated for IgM and malaria.

Interference with Fcα/μRs

Fcα/μR, a human receptor for IgM (and IgA) closely related to the polymeric IgR in its ligand-binding domain, has also been described (48–50). Expressed predominantly on follicular dendritic cells (FDCs), Fcα/μR is believed to function in Ag presentation and B cell selection in the germinal center response (42, 51). Recent work in Fcα/μR knockout mice suggests that the receptor negatively regulates T-independent Ag (common in malaria) retention by FDCs, culminating in the suppression of humoral immune responses against T-independent Ags (52). The receptor can also mediate endocytosis of IgM-coated bacteria and immune complexes (48–50). Therefore, IgM binding by PfEMP1 may allow infected erythrocytes to interfere with these functions of Fcα/μR. We recently showed that the binding of IgM to Fcα/μR is dependent on the pentameric structure of IgM and that mAbs that inhibit binding to PfEMP1 also prevent binding of IgM

to Fcα/μR (53), suggesting that the binding sites for the two ligands lie close to each other on IgM. By using domain-swapped Abs, we demonstrated that binding involved the Cμ3 and Cμ4 domains in the IgM polymer, and similar results were recently observed with FcμR (42). However, the 80-kDa secretory component that shares homologous binding sites with Fcα/μR does not block the binding of IgM to DBL4β, implying that IgM can accommodate the simultaneous binding of both ligands (16, 53). It is known that the interaction with Fcα/μR requires unique amino acid contacts in IgM, because domain-swap Abs containing only Cμ4 bind PfEMP1 but do not bind Fcα/μR. Furthermore, mouse IgM does not bind PfEMP1, yet it is capable of binding human Fcα/μR and FcμR, supporting our notion that unique contacts are involved in the binding of human IgM to PfEMP1 or Fcα/μR and FcμR. Given the overlapping nature of the binding sites, it could be argued that this region is important for human IgM function and that it is beneficial for the infected erythrocyte to manipulate the receptor's access to this region.

Interference with complement

The ability of IgM to agglutinate and neutralize pathogens so effectively is largely due to its polymeric structure that endows the molecule with increased avidity. This unique structure also makes IgM very effective at activating the classical complement cascade. A single molecule of IgM can trigger complement activation, leading to the lysis of a single erythrocyte, an equivalent task requiring 1000 IgG molecules (44, 54).

Therefore, binding of PfEMP1 at the interface of the IgM Cμ4 domain offers an elegant explanation for our finding that C1q binding did not interfere with the DBL domain interaction (16), because the residues involved in C1q binding are found in the Cμ3 domain on the flat side of the IgM molecule (Fig. 4) (34). However, IgM binding by PfEMP1 might interfere with complement activation by inducing

FIGURE 4. C1q-binding sites in the IgM–DBL4β complex. The image shows the IgM–DBL4β model looking down onto the flat side of the IgM molecule, where the putative C1q-binding sites on IgM (green) are located (34). It is clear that C1q would not be expected to sterically interfere with DBL4β binding to IgM, consistent with experimental observations (16).

conformational changes in the central core of IgM that lock out the C1q-binding sites on IgM. Alternatively, PfEMP1 binding may force IgM to be oriented with its flat side directly facing the red cell membrane, making the C1q-binding sites inaccessible to C1q.

If these hypotheses are correct, C1q would rarely be found bound to infected erythrocytes. Although no published studies have reported the presence of C1q on infected erythrocytes, parasite-specific IgM and other complement factors, including C3, C4, and C9, have been described on infected erythrocytes (55). However, these can all be deposited via the alternative or lectin pathways in a manner independent of C1q or IgM. Although we know that DBL binding can occur to IgM opsonized onto haptenated erythrocytes, we still do not know whether PfEMP1 binding can occur after engagement of an infected erythrocyte by parasite-specific IgM and what effect this might have on subsequent C1q docking. Human IgM mAbs against other knob-associated Ag(s) or non-IgM–binding DBL domains would clearly be useful to address these questions.

Interference with the BCR

Infection with *P. falciparum* induces a hypergammaglobulinemia indicative of the presence of B cell mitogens (43). We have become intrigued by the possibility that these various DBL domains may interact directly with IgM⁺ B cells through the BCR, because Cμ4-specific mAbs that inhibit PfEMP1 binding to IgM were also shown to augment S-phase entry of human B cells via the IgM⁺ BCR (16, 56). IgM-mediated signaling is required for the development of a normal B cell memory response (57). Our finding that malaria parasites, known to promote polyclonal B cell activation, encode molecules specific for Cμ4 certainly suggests that binding to this region of the BCR might also be immunologically important and merits further investigation. Although most circulating infected erythrocytes will presumably be saturated in IgM, making them unable to simultaneously engage IgM⁺ B cells through the same DBL domain, other regions of PfEMP1 may contact the IgM⁺ BCR after the primary IgM contact. One candidate is the cysteine-rich interdomain region domain, which is already known to interact directly with the B cell (58).

Evidence demonstrating the ability of the BCR to cluster could support the idea that PfEMP1 may bind to the Cμ4 of the BCR and to soluble pentameric IgM via similar mechanisms. It is well known that BCR mutants missing the Cμ4 domain are unable to inhibit signaling upon Ag binding and that Cμ4 domains expressed alone on the B cell surface cluster spontaneously to activate the cell (56, 59, 60). Therefore, the DBL domain may cross-link two BCR monomers [as in the model with pentameric IgM (Figs. 2, 3)], or binding may induce conformational changes in the BCR, revealing an interface that promotes BCR clustering with subsequent uncontrolled activation. Coincidently, the BCR governs the subcellular location of TLR 9, a ligand for *Plasmodium* DNA that leads to hyperresponses to DNA-containing Ags (60, 61). Whether FcμR, potentially as a coreceptor at the surface of the B cell, plays a role in BCR function and memory induction and the potential role for interference by malaria parasites through IgM binding now need to be investigated, perhaps in FcμR-deficient mouse models of malaria.

Interference with endothelial receptors

Sequestration of infected erythrocytes in the microvasculature and the placenta is a cardinal feature of *P. falciparum* infection; it is thought to benefit the parasite by allowing infected erythrocytes to avoid being removed by the spleen (27). It is possible that IgM bound to infected erythrocytes could cross-bridge to host IgM-binding receptors on endothelial or placental cells to promote the sequestration of parasitized cells. It is unknown whether any of the IgM receptors discussed above are expressed on human endothelial cells in the microvasculature or on placental syncytiotrophoblast cells. One intriguing recent finding is that CD300LG (also known as CLM9, TREM4, or NEPMUCIN) shares 35% identity with Fcα/μR and is expressed on capillary endothelium, particularly in placental tissues (62). Although CD300LG is a functional receptor for L-selectin–mediated lymphocyte rolling (63), it was recently shown to bind IgM (62). Future experiments should investigate the expression patterns of IgM-binding proteins in the human microvasculature and placenta and address the possibility that IgM (natural or parasite-specific) bound to infected erythrocytes could cross-bridge to promote sequestration.

Interference with neutralizing and adhesion-blocking Abs

Rosetting and placental parasite isolates may also bind non-specific IgM to allow masking of critical PfEMP1 domains from the destructive action of specific Abs, e.g., IgG. This "umbrella" hypothesis is supported by the observation that the domain adjacent to the IgM-binding domain in *var2csa* seems to be the only domain inducing highly adhesion-blocking Abs in humans. The hypothesis is readily testable using domain-specific and parasite adhesion-blocking anti-*var2csa* IgG (64).

Conclusions

The ability of diverse *P. falciparum* isolates to bind a conserved region of the IgM Fc suggests that this function is essential to parasite survival. Therefore, a molecular understanding of how malaria parasites bind the Fc of natural and specific IgM may lead to the development of novel inhibitors of this interaction. For example, small molecule inhibitors may prevent docking of PfEMP1 to IgM or the BCR and prevent hypergammaglobulinemia or, in the case of immunity, lead to the development of greater memory responses when coinjected with vaccines. Understanding how infected erythrocytes manipulate IgM may also lead to the development of improved adjuvants based on the remarkable properties of this fascinating molecule (12, 14). DBL-based reagents, like those already developed for bacterial protein A and G, may be used for the specific detection and purification of human IgM. As such, they promise to become valuable tools for structural and functional studies of IgM.

Acknowledgments

Disclosures

The authors have no financial conflicts of interest.

References

1. Fellah, J. S., M. V. Wiles, J. Charlemagne, and J. Schwager. 1992. Evolution of vertebrate IgM: complete amino acid sequence of the constant region of *Ambystoma mexicanum* mu chain deduced from cDNA sequence. *Eur. J. Immunol.* 22: 2595–2601.
2. Ye, J., E. S. Bromage, and S. L. Kaattari. 2010. The strength of B cell interaction with antigen determines the degree of IgM polymerization. *J. Immunol.* 184: 844–850.
3. Ochsenbein, A. F., T. Fehr, C. Lutz, M. Suter, F. Brombacher, H. Hengartner, and R. M. Zinkernagel. 1999. Control of early viral and bacterial distribution and disease by natural antibodies. *Science* 286: 2156–2159.
4. Boes, M., A. P. Prodeus, T. Schmidt, M. C. Carroll, and J. Chen. 1998. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. *J. Exp. Med.* 188: 2381–2386.
5. Alugupalli, K. R., J. M. Leong, R. T. Woodland, M. Muramatsu, T. Honjo, and R. M. Gerstein. 2004. B1b lymphocytes confer T cell-independent long-lasting immunity. *Immunity* 21: 379–390.
6. Baumgarth, N., O. C. Herman, G. C. Jager, L. Brown, L. A. Herzenberg, and L. A. Herzenberg. 1999. Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. *Proc. Natl. Acad. Sci. USA* 96: 2250–2255.
7. McGue, M., I. B. Borecki, J. W. Gerrard, and D. C. Rao. 1990. Sex-linked determinants for IgM? *Hum. Hered.* 40: 231–234.
8. Adinolfi, M., S. A. Haddad, and M. J. Seller. 1978. X chromosome complement and serum levels of IgM in man and mouse. *J. Immunogenet.* 5: 149–156.
9. Washburn, T. C., D. N. Medearis Jr., and B. Childs. 1965. Sex differences in susceptibility to infections. *Pediatrics* 35: 57–64.
10. Hobbs, J. R., R. D. Milner, and P. J. Watt. 1967. Gamma-M deficiency predisposing to meningococcal septicaemia. *Br. Med. J.* 4: 583–586.
11. Racine, R., and G. M. Winslow. 2009. IgM in microbial infections: taken for granted? *Immunol. Lett.* 125: 79–85.
12. Harte, P. G., A. Cooke, and J. H. Playfair. 1983. Specific monoclonal IgM is a potent adjuvant in murine malaria vaccination. *Nature* 302: 256–258.
13. Couper, K. N., C. W. Roberts, F. Brombacher, J. Alexander, and L. L. Johnson. 2005. *Toxoplasma gondii*-specific immunoglobulin M limits parasite dissemination by preventing host cell invasion. *Infect. Immun.* 73: 8060–8068.
14. Stäger, S., J. Alexander, A. C. Kirby, M. Botto, N. V. Rooijen, D. F. Smith, F. Brombacher, and P. M. Kaye. 2003. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. *Nat. Med.* 9: 1287–1292.
15. Rowe, J. A., J. Shafi, O. K. Kai, K. Marsh, and A. Raza. 2002. Nonimmune IgM, but not IgG binds to the surface of *Plasmodium falciparum*-infected erythrocytes and correlates with rosetting and severe malaria. *Am. J. Trop. Med. Hyg.* 66: 692–699.
16. Ghumra, A., J. P. Semblat, R. S. McIntosh, A. Raza, I. B. Rasmussen, R. Braathen, F. E. Johansen, I. Sandlie, P. K. Mongini, J. A. Rowe, and R. J. Pleass. 2008. Identification of residues in the Cmu4 domain of polymeric IgM essential for interaction with *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1). *J. Immunol.* 181: 1988–2000.
17. Creasey, A. M., T. Staalsoe, A. Raza, D. E. Arnot, and J. A. Rowe. 2003. Nonspecific immunoglobulin M binding and chondroitin sulfate A binding are linked phenotypes of *Plasmodium falciparum* isolates implicated in malaria during pregnancy. *Infect. Immun.* 71: 4767–4771.
18. Fried, M., and P. E. Duffy. 1996. Adherence of *Plasmodium falciparum* to chondroitin sulfate A in the human placenta. *Science* 272: 1502–1504.
19. Nezlin, R., and V. Ghetie. 2004. Interactions of immunoglobulins outside the antigen-combining site. *Adv. Immunol.* 82: 155–215.
20. Pleass, R. J., and J. M. Woof. 2001. Fc receptors and immunity to parasites. *Trends Parasitol.* 17: 545–551.
21. Pleass, R. J., T. Areschoug, G. Lindahl, and J. M. Woof. 2001. Streptococcal IgA-binding proteins bind in the Calpha 2-Calpha 3 interdomain region and inhibit binding of IgA to human CD89. *J. Biol. Chem.* 276: 8197–8204.
22. Vercammen, M., T. Scorza, A. El Bouhdidi, K. Van Beeck, Y. Carlier, J. F. Dubremetz, and H. Verschueren. 1999. Opsonization of *Toxoplasma gondii* tachyzoites with nonspecific immunoglobulins promotes their phagocytosis by macrophages and inhibits their proliferation in nonphagocytic cells in tissue culture. *Parasite Immunol.* 21: 555–563.
23. Vincendeau, P., and M. Daëron. 1989. *Trypanosoma musculi* co-express several receptors binding rodent IgM, IgE, and IgG subclasses. *J. Immunol.* 142: 1702–1709.
24. Baruch, D. I., B. L. Pasloske, H. B. Singh, X. Bi, X. C. Ma, M. Feldman, T. F. Taraschi, and R. J. Howard. 1995. Cloning the *P. falciparum* gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. *Cell* 82: 77–87.
25. Smith, J. D., C. E. Chitnis, A. G. Craig, D. J. Roberts, D. E. Hudson-Taylor, D. S. Peterson, R. Pinches, C. I. Newbold, and L. H. Miller. 1995. Switches in expression of *Plasmodium falciparum* var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. *Cell* 82: 101–110.
26. Kyes, S. A., S. M. Kraemer, and J. D. Smith. 2007. Antigenic variation in *Plasmodium falciparum*: gene organization and regulation of the var multigene family. *Eukaryot. Cell* 6: 1511–1520.
27. Kraemer, S. M., and J. D. Smith. 2006. A family affair: var genes, PfEMP1 binding, and malaria disease. *Curr. Opin. Microbiol.* 9: 374–380.
28. Gardner, M. J., N. Hall, E. Fung, O. White, M. Berriman, R. W. Hyman, J. M. Carlton, A. Pain, K. E. Nelson, S. Bowman, et al. 2002. Genome sequence of the human malaria parasite *Plasmodium falciparum*. *Nature* 419: 498–511.
29. Chen, Q., A. Heddini, A. Barragan, V. Fernandez, S. F. Pearce, and M. Wahlgren. 2000. The semiconserved head structure of *Plasmodium falciparum* erythrocyte membrane protein 1 mediates binding to multiple independent host receptors. *J. Exp. Med.* 192: 1–10.

30. Flick, K., C. Scholander, Q. Chen, V. Fernandez, B. Pouvelle, J. Gysin, and M. Wahlgren. 2001. Role of nonimmune IgG bound to PfEMP1 in placental malaria. *Science* 293: 2098–2100.

31. Semblat, J. P., A. Raza, S. A. Kyes, and J. A. Rowe. 2006. Identification of *Plasmodium falciparum* var1CSA and var2CSA domains that bind IgM natural antibodies. *Mol. Biochem. Parasitol.* 146: 192–197.

32. Rasti, N., F. Namusoke, A. Chêne, Q. Chen, T. Staalsoe, M. Q. Klinkert, F. Mirembe, F. Kironde, and M. Wahlgren. 2006. Nonimmune immunoglobulin binding and multiple adhesion characterize *Plasmodium falciparum*-infected erythrocytes of placental origin. *Proc. Natl. Acad. Sci. USA* 103: 13795–13800.

33. Resende, M., S. B. Ditlev, M. A. Nielsen, S. Bodevin, S. Bruun, V. V. Pinto, H. Clausen, L. Turner, T. G. Theander, A. Salanti, and M. Dahlbäck. 2009. Chondroitin sulphate A (CSA)-binding of single recombinant Duffy-binding-like domains is not restricted to *Plasmodium falciparum* Erythrocyte Membrane Protein 1 expressed by CSA-binding parasites. *Int. J. Parasitol.* 39: 1195–1204.

34. Czajkowsky, D. M., and Z. Shao. 2009. The human IgM pentamer is a mushroom-shaped molecule with a flexural bias. *Proc. Natl. Acad. Sci. USA* 106: 14960–14965.

35. Higgins, M. K. 2008. The structure of a chondroitin sulfate-binding domain important in placental malaria. *J. Biol. Chem.* 283: 21842–21846.

36. Khunrae, P., J. M. Philip, D. R. Bull, and M. K. Higgins. 2009. Structural comparison of two CSPG-binding DBL domains from the VAR2CSA protein important in malaria during pregnancy. *J. Mol. Biol.* 393: 202–213.

37. Tolia, N. H., E. J. Enemark, B. K. Sim, and L. Joshua-Tor. 2005. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite *Plasmodium falciparum*. *Cell* 122: 183–193.

38. Singh, S. K., R. Hora, H. Belrhali, C. E. Chitnis, and A. Sharma. 2006. Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain. *Nature* 439: 741–744.

39. Singh, K., A. G. Gittis, P. Nguyen, D. C. Gowda, L. H. Miller, and D. N. Garboczi. 2008. Structure of the DBL3x domain of pregnancy-associated malaria protein VAR2CSA complexed with chondroitin sulfate A. *Nat. Struct. Mol. Biol.* 15: 932–938.

40. Le Naour, F., S. Charrin, V. Labas, J. P. Le Caer, C. Boucheix, and E. Rubinstein. 2004. Tetraspanins connect several types of Ig proteins: IgM is a novel component of the tetraspanin web on B-lymphoid cells. *Cancer Immunol. Immunother.* 53: 148–152.

41. Silvie, O., E. Rubinstein, J. F. Franetich, M. Prenant, E. Belnoue, L. Rénia, L. Hannoun, W. Eling, S. Levy, C. Boucheix, and D. Mazier. 2003. Hepatocyte CD81 is required for *Plasmodium falciparum* and *Plasmodium yoelii* sporozoite infectivity. *Nat. Med.* 9: 93–96.

42. Kubagawa, H., S. Oka, Y. Kubagawa, I. Torii, E. Takayama, D. W. Kang, G. L. Gartland, L. F. Bertoli, H. Mori, H. Takatsu, et al. 2009. Identity of the elusive IgM Fc receptor (FcmuR) in humans. *J. Exp. Med.* 206: 2779–2793.

43. Greenwood, B. M., and R. M. Vick. 1975. Evidence for a malaria mitogen in human malaria. *Nature* 257: 592–594.

44. Carroll, M. C. 2004. The complement system in regulation of adaptive immunity. *Nat. Immunol.* 5: 981–986.

45. Rochford, R., M. J. Cannon, and A. M. Moormann. 2005. Endemic Burkitt's lymphoma: a polymicrobial disease? *Nat. Rev. Microbiol.* 3: 182–187.

46. Chêne, A., D. Donati, A. O. Guerreiro-Cacais, V. Levitsky, Q. Chen, K. I. Falk, J. Orem, F. Kironde, M. Wahlgren, and M. T. Bejarano. 2007. A molecular link between malaria and Epstein-Barr virus reactivation. *PLoS Pathog.* 3: e80.

47. Overstreet, M. G., I. A. Cockburn, Y. C. Chen, and F. Zavala. 2008. Protective CD8 T cells against *Plasmodium* liver stages: immunobiology of an 'unnatural' immune response. *Immunol. Rev.* 225: 272–283.

48. Shibuya, A., N. Sakamoto, Y. Shimizu, K. Shibuya, M. Osawa, T. Hiroyama, H. J. Eyre, G. R. Sutherland, Y. Endo, T. Fujita, et al. 2000. Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. *Nat. Immunol.* 1: 441–446.

49. Sakamoto, N., K. Shibuya, Y. Shimizu, K. Yotsumoto, T. Miyabayashi, S. Sakano, T. Tsuji, E. Nakayama, H. Nakauchi, and A. Shibuya. 2001. A novel Fc receptor for IgA and IgM is expressed on both hematopoietic and non-hematopoietic tissues. *Eur. J. Immunol.* 31: 1310–1316.

50. Cho, Y., S. I. Honda, Y. Yoshizawa, K. Takagaki, K. Usui, and A. Shibuya. 2010. Requirement of the cytoplasmic portion for dimer formation of Fcalpha/micro receptor expressed on cell surface. *Mol. Immunol.* 47: 878–882 .

51. Kikuno, K., D. W. Kang, K. Tahara, I. Torii, H. M. Kubagawa, K. J. Ho, L. Baudino, N. Nishizaki, A. Shibuya, and H. Kubagawa. 2007. Unusual biochemical features and follicular dendritic cell expression of human Fcalpha/mu receptor. *Eur. J. Immunol.* 37: 3540–3550.

52. Honda, S., N. Kurita, A. Miyamoto, Y. Cho, K. Usui, K. Takeshita, S. Takahashi, T. Yasui, H. Kikutani, T. Kinoshita, et al. 2009. Enhanced humoral immune responses against T-independent antigens in Fc alpha/muR-deficient mice. *Proc. Natl. Acad. Sci. USA* 106: 11230–11235.

53. Ghumra, A., J. Shi, R. S. Mcintosh, I. B. Rasmussen, R. Braathen, F. E. Johansen, I. Sandlie, P. K. Mongini, T. Areschoug, G. Lindahl, et al. 2009. Structural requirements for the interaction of human IgM and IgA with the human Fcalpha/mu receptor. *Eur. J. Immunol.* 39: 1147–1156.

54. Cooper, N. R. 1985. The classical complement pathway: activation and regulation of the first complement component. *Adv. Immunol.* 37: 151–216.

55. Wiesner, J., H. Jomaa, M. Wilhelm, H. P. Tony, P. G. Kremsner, P. Horrocks, and M. Lanzer. 1997. Host cell factor CD59 restricts complement lysis of *Plasmodium falciparum*-infected erythrocytes. *Eur. J. Immunol.* 27: 2708–2713.

56. Mongini, P. K., C. A. Blessinger, N. Chiorazzi, N. Rajaram, and S. M. Rudich. 1995. A monovalent C μ 4-specific ligand enhances the activation of human B cells by membrane IgM cross-linking ligands. *Int. Immunol.* 7: 317–330.

57. Guo, L., X. Zhang, B. Zheng, and S. Han. 2008. IgM-mediated signaling is required for the development of a normal B cell memory response. *Mol. Immunol.* 45: 1071–1077.

58. Donati, D., B. Mok, A. Chêne, H. Xu, M. Thangarajh, R. Glas, Q. Chen, M. Wahlgren, and M. T. Bejarano. 2006. Increased B cell survival and preferential activation of the memory compartment by a malaria polyclonal B cell activator. *J. Immunol.* 177: 3035–3044.

59. Tolar, P., J. Hanna, P. D. Krueger, and S. K. Pierce. 2009. The constant region of the membrane immunoglobulin mediates B cell-receptor clustering and signaling in response to membrane antigens. *Immunity* 30: 44–55.

60. Pierce, S. K. 2009. Understanding B cell activation: from single molecule tracking, through Tolls, to stalking memory in malaria. *Immunol. Res.* 43: 85–97.

61. Chaturvedi, A., D. Dorward, and S. K. Pierce. 2008. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. *Immunity* 28: 799–809.

62. Takatsu, H., K. Hase, M. Ohmae, S. Ohshima, K. Hashimoto, N. Taniura, A. Yamamoto, and H. Ohno. 2006. CD300 antigen like family member G: A novel Ig receptor like protein exclusively expressed on capillary endothelium. *Biochem. Biophys. Res. Commun.* 348: 183–191.

63. Umemoto, E., T. Tanaka, H. Kanda, S. Jin, K. Tohya, K. Otani, T. Matsutani, M. Matsumoto, Y. Ebisuno, M. H. Jang, et al. 2006. Nepmucin, a novel HEV sialomucin, mediates L-selectin-dependent lymphocyte rolling and promotes lymphocyte adhesion under flow. *J. Exp. Med.* 203: 1603–1614.

64. Nielsen, M. A., V. V. Pinto, M. Resende, M. Dahlbäck, S. B. Ditlev, T. G. Theander, and A. Salanti. 2009. Induction of adhesion-inhibitory antibodies against placental *Plasmodium falciparum* parasites by using single domains of VAR2CSA. *Infect. Immun.* 77: 2482–2487.